摘要 ：统计22家国内上市仪器公司2025年业绩预告数据，拆解各企业业绩变动核心原因，剖析行业发展现状与趋势，为 市场参与者提供参考。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2026 年初以来，国内仪器行业上市企业陆续披露 2025 年业绩预告，行业整体经营态势逐步清晰。本文对 统计到的 22 家国产仪器厂商业绩预告进行系统梳理，涵盖多个细分领域， 为市场参与者提供参考。 从净利润来看， 共有11家企业盈利，11家企业亏损；与上年同期相比，盈利企业中8家实现同比增长，3家 盈利但增速平缓或略有波动，亏损企业中4家实现亏损收窄，7家出现亏损扩大或由盈转亏。 可以看出，在 国内下游需求波动、行业竞争持续加剧、政策环境调整及全球供应链不稳定的多重背景下，国产仪器行业业 绩分化态势进一步加剧，部分企业凭借前瞻性的战略布局实现增长，展现出强劲的经营韧性，而部分企业则 受困于业务转型、资产减值等因素，面临阶段性经营压力。 埃 科 光 电 | | | 2025年度国产仪器上市企业净利润统计表 | | | | --- | --- | --- | ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

[Table_Page] 跟踪分析|环保 证券研究报告 [Table_Title] 环保行业深度跟踪 业绩期即将到来，碳减排攻坚力度可期 [Table_Summary] 核心观点： | [Table_Grade] 行业评级 | 买入 | | --- | --- | | 前次评级 | 买入 | | 报告日期 | 2026-02-01 | [Table_Pic 相对市场表现 2025Quote] -10% -3% 4% 10% 17% 24% 10/24 01/25 03/25 05/25 08/25 10/25 环保 沪深300 | [Table_Author 分析师： ]陈龙 | | | --- | --- | | | SAC 执证号：S0260523030004 | | | 021-38003623 | | | shchenlong@gf.com.cn | | 分析师： | 郭鹏 | | | SAC 执证号：S0260514030003 | | | SFC CE No. BNX688 | | | 021-38003655 | | | guopeng@gf.com.cn | | 分析师： | 荣凌琪 | | ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近期，皖仪科技发布2025年业绩预告： 一、本期业绩预告情况 （一）业绩预告期间 2 0 2 5 年1月1日至2 0 2 5年1 2月3 1日。 二、上年同期业绩情况 公司2 0 2 4年年度实现利润总额2 , 7 3 6 . 2 5万元，归属于母公司所有者的净利润1 , 4 4 0 . 7 3 万元， 归属于母公司所有者的扣除非经常性损益的净利润- 1 9 7 . 4 2万 元，每股收益0 . 11元。 三、本期业绩变化 的主要 原因 报告期内，公司持续提升运营管理效率，通过产品结构优化和多项降本增效措施，实现了综合 销售毛利率同比增长以及期间费用同比下降。同时，随研发项 目的开展本期政府补助较上年同 比增加。综上，公司2 0 2 5年度归属于母公司所 有者的净利润和归属于母公司所有者的扣除非 经常性损益的净利润均同比增加。 四、风险提示 本次业绩预告是公司财务部门基于自身专业判断进行的初步核算，未经会计师事务所审计。截 至本公告披露日，公司尚未发现影响本次业绩预告内容准确性 的重大不确定 ...

专题：交易提示 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 【停牌】 002231 *ST奥维（维权） 300666 江丰电子 300344 *ST立方（维权） 【复牌】 *ST奥维：收到终止上市事先告知书股票于1月30日起停牌 无 【品大事】 美年健康：拟参与棒杰股份预重整 美年健康（002044）公告，公司拟报名参与浙江棒杰控股集团股份有限公司（简称"棒杰股份"）重整投 资人的公开招募，并指定下属全资子公司美年大健康为重整受让主体取得棒杰股份的控制权，成为棒杰 股份重整完成后的控股股东。是否具有参与资格以及最终能否成为重整投资人尚存在不确定性。 白银有色（维权）：公司黄金、白银产品的收入占总营业收入比重较低 白银有色（601212）发布股票交易异常波动及严重异常波动公告称，公司黄金、白银产品的收入占总营 业收入的比重较低。2025年上半年，公司营业收入445.59亿元，销售黄金产品收入83.18亿元，占公司营 业收入的比重18.67%，销售白银产品收入20.23亿元，占公司营业收入的比重4.54%。 天顺风能：决定对六家全资子公司实施长期停产安排 天顺风能（002531）公告 ...

皖仪科技(688600.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润为4200万元到 6200万元，与上年同期(法定披露数据)相比，将增加2,759.27万元到4,759.27万元，同比增加191.52%到 330.34%。 ...

证券日报网讯 1月29日，皖仪科技发布公告称，公司预计 2025 年年度实现归属于母公司所有者的净利 润为 4，200 万元到 6，200 万元，与上年同期（法定披露数据）相比，将增加 2，759.27万元到 4， 759.27 万元，同比增加 191.52%到 330.34%。 （编辑 楚丽君） ...

智通财经APP讯，皖仪科技(688600.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润为4200万元到6200万元，与上年同期(法定披露数据)相比，将增加2,759.27万元到4,759.27万元，同 比增加191.52%到330.34%。 ...

Group 1 - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder after the completion of the restructuring [3] - Baiyin Nonferrous Metals reported that the revenue from gold and silver products accounted for a low proportion of total operating income, with gold sales contributing 18.67% and silver sales 4.54% in the first half of 2025 [4] - Tiens Wind Power decided to implement a long-term production suspension for six wholly-owned subsidiaries to optimize resource allocation and focus on core businesses [5] Group 2 - Tongling Nonferrous Metals indicated significant uncertainty in the price fluctuations of its main products, with a low self-sufficiency rate for copper concentrate posing supply stability risks [6] - *ST Aowei received a notice of termination of listing due to its market capitalization falling below 500 million yuan for twenty consecutive trading days [7] - Foton Motor expects a net profit increase of approximately 1551% year-on-year for 2025, driven by sales growth in new energy vehicles and overseas markets [9] Group 3 - Beimo High-tech anticipates a net profit increase of 1076.16% to 1261.87% for 2025, supported by cost control and reduced credit impairment losses [10] - Zhongke Sanhuan forecasts a net profit growth of 566.23% to 899.35% for 2025, attributed to technological innovation and improved operational efficiency [12] - Wancheng Group expects a net profit increase of 222.38% to 266.94% for 2025, driven by growth in its retail business and improved sales margins [13] Group 4 - Huayi Technology anticipates a net profit increase of 191.52% to 330.34% for 2025, benefiting from product optimization and cost reduction measures [14] - Nanmo Biology expects a net profit growth of 269.49% to 423.44% for 2025, supported by increased revenue in the biopharmaceutical sector and improved cost control [15] - Baiao Saitu forecasts a net profit increase of 384.26% to 443.88% for 2025, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [16] Group 5 - Hailanxin expects a net profit increase of 387.47% to 631.2% for 2025, supported by advancements in technology and increased market share in marine observation [17] - Panjiang Co. anticipates a net profit growth of 205.3% to 264.83% for 2025, driven by increased coal production and reduced costs [18] - Huaguang New Materials expects a net profit increase of 104.67% to 141.88% for 2025, with significant growth in the electronic sector [20] Group 6 - Guo Sheng Securities forecasts a net profit increase of 25.44% to 67.25% for 2025, supported by active capital market participation and growth in various business segments [25] - Shengyi Technology expects a net profit growth of 87% to 98% for 2025, driven by increased sales of copper-clad laminates [26] - Sifutian anticipates a net loss of 30 million to 45 million yuan for 2025, although this represents a significant reduction in losses compared to the previous year [27] Group 7 - Maanshan Steel expects a net loss of 1.9 billion to 2.5 billion yuan for 2025, with a substantial reduction in losses compared to the previous year [28] - Shennong Seed Industry forecasts a net profit of 90 million to 120 million yuan for 2025, marking a turnaround from previous losses [30] - Jifeng Co. anticipates a net profit of 410 million to 495 million yuan for 2025, achieving a turnaround from losses [31]

皖仪科技公告，预计2025年度归属于母公司所有者的净利润为4200万元到6200万元，同比增加191.52% —330.34%。报告期内，通过产品结构优化和多项降本增效措施，实现了综合销售毛利率同比增长以及 期间费用同比下降。同时，随研发项目的开展本期政府补助较上年同比增加。 ...